社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
yvo92
IP属地：未知
+关注
帖子 · 11
帖子 · 11
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
yvo92
yvo92
·
2021-07-01
Nice
非常抱歉，此主贴已删除
看
1,931
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-25
Good
非常抱歉，此主贴已删除
看
1,920
回复
评论
点赞
1
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-23
Good
非常抱歉，此主贴已删除
看
2,116
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-21
Nice
Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme 在盘前交易中上涨超过 6%</blockquote>
(June 21) Orphazyme rose more than 6% in premarket trading. What happened Shares of Orphazyme, a c
Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme 在盘前交易中上涨超过 6%</blockquote>
看
2,013
回复
2
点赞
2
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-18
Wow
非常抱歉，此主贴已删除
看
3,667
回复
评论
点赞
2
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-18
Good
非常抱歉，此主贴已删除
看
1,821
回复
评论
点赞
5
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-17
Bad
Musk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>疫苗受挫后，马斯克吹捧的 CureVac 价值损失了 49%</blockquote>
Company plunges After Covid Shot Falls Short With 47% Efficacy Effectiveness is far below that seen
Musk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>疫苗受挫后，马斯克吹捧的 CureVac 价值损失了 49%</blockquote>
看
2,138
回复
评论
点赞
4
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-16
Nice
非常抱歉，此主贴已删除
看
2,129
回复
1
点赞
1
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-15
Hi everybody
看
1,965
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-15
Nice
非常抱歉，此主贴已删除
看
1,402
回复
评论
点赞
2
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3575604969719218","uuid":"3575604969719218","gmtCreate":1612787974300,"gmtModify":1612787974300,"name":"yvo92","pinyin":"yvo92","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.08.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":158368602,"gmtCreate":1625130308506,"gmtModify":1633944469275,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575604969719218","authorIdStr":"3575604969719218"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158368602","repostId":"1198389317","repostType":4,"isVote":1,"tweetType":1,"viewCount":1931,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122559363,"gmtCreate":1624628563952,"gmtModify":1633950344693,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575604969719218","authorIdStr":"3575604969719218"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/122559363","repostId":"2146023477","repostType":4,"isVote":1,"tweetType":1,"viewCount":1920,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123681976,"gmtCreate":1624420771695,"gmtModify":1634006355071,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575604969719218","authorIdStr":"3575604969719218"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123681976","repostId":"1116451605","repostType":4,"isVote":1,"tweetType":1,"viewCount":2116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167562823,"gmtCreate":1624278271462,"gmtModify":1634008539969,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575604969719218","authorIdStr":"3575604969719218"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/167562823","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://www.laohunote.com/m/news/1184501396?lang=zh_CN&edition=full","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme 在盘前交易中上涨超过 6%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21) Orphazyme rose more than 6% in premarket trading. </p><p><blockquote>（6月21日）Orphazyme在盘前交易中上涨超过6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么事</b></blockquote></p><p> Shares of <b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.</p><p><blockquote>股份<b>奥尔法酶</b>在美国食品药品监督管理局 (FDA) 拒绝批准该公司主要候选人的申请后，一家临床阶段的生物制药公司受到了打击。投资者现在不确定这家生物技术公司何时可以销售获得批准的产品，截至美国东部时间中午 12:12，该股下跌 44.4%。上周五美国东部时间。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p><p><blockquote>FDA 去年 9 月开始审查 Orphazyme 的主要候选药物 arimoclomol 的申请，作为一种罕见但危及生命的疾病的潜在治疗方法，称为 Neimann-Pick 病 C 型 (NPC)。本月早些时候，Orphazyme 的股价上涨了 200% 以上，原因是预期从未到来的绿灯。</blockquote></p><p> Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p><p><blockquote>该机构没有做出arimoclomol的批准决定，而是以完整回复函（CRL）的形式要求提供更多信息。这让许多投资者感到震惊，他们刚刚接触复杂的药物开发世界，并预计会出现大规模的空头挤压。</blockquote></p><p> Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p><p><blockquote>许多机构投资者押注 Orphazyme，因为其主要候选药物未能在支撑该申请的关键研究中实现主要终点。Arimoclomol 也未能改善 FDA 特别要求的次要终点的患者评分。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在呢</b></blockquote></p><p> According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p><p><blockquote>据Orphazyme称，该公司需要进一步证实arimoclomol几乎达到的主要终点的有效性。为了满足 FDA 的要求，该公司很可能不得不进行一项新的关键研究。</blockquote></p><p> Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p><p><blockquote>一些股东仍然希望欧洲药品管理局不会像FDA那样严格。虽然FDA的欧洲同事过去在罕见疾病的治疗方面更加宽松，但arimoclomol可能不会向前推进，直到它产生一些令人信服的临床试验结果。</blockquote></p><p> Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p><p><blockquote>尽管缺乏明确的前进道路，这家总部位于丹麦的公司仍然拥有相当大的市值，按最近的价格计算，超过 5 亿美元。非理性的期望可能会使其保持较高水平，但对于任何临床阶段的生物技术公司 Orphazyme 的地位来说，这都太高了。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme 在盘前交易中上涨超过 6%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading<blockquote>Orphazyme 在盘前交易中上涨超过 6%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-06-21 17:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(June 21) Orphazyme rose more than 6% in premarket trading. </p><p><blockquote>（6月21日）Orphazyme在盘前交易中上涨超过6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么事</b></blockquote></p><p> Shares of <b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.</p><p><blockquote>股份<b>奥尔法酶</b>在美国食品药品监督管理局 (FDA) 拒绝批准该公司主要候选人的申请后，一家临床阶段的生物制药公司受到了打击。投资者现在不确定这家生物技术公司何时可以销售获得批准的产品，截至美国东部时间中午 12:12，该股下跌 44.4%。上周五美国东部时间。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p><p><blockquote>FDA 去年 9 月开始审查 Orphazyme 的主要候选药物 arimoclomol 的申请，作为一种罕见但危及生命的疾病的潜在治疗方法，称为 Neimann-Pick 病 C 型 (NPC)。本月早些时候，Orphazyme 的股价上涨了 200% 以上，原因是预期从未到来的绿灯。</blockquote></p><p> Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p><p><blockquote>该机构没有做出arimoclomol的批准决定，而是以完整回复函（CRL）的形式要求提供更多信息。这让许多投资者感到震惊，他们刚刚接触复杂的药物开发世界，并预计会出现大规模的空头挤压。</blockquote></p><p> Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p><p><blockquote>许多机构投资者押注 Orphazyme，因为其主要候选药物未能在支撑该申请的关键研究中实现主要终点。Arimoclomol 也未能改善 FDA 特别要求的次要终点的患者评分。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在呢</b></blockquote></p><p> According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p><p><blockquote>据Orphazyme称，该公司需要进一步证实arimoclomol几乎达到的主要终点的有效性。为了满足 FDA 的要求，该公司很可能不得不进行一项新的关键研究。</blockquote></p><p> Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p><p><blockquote>一些股东仍然希望欧洲药品管理局不会像FDA那样严格。虽然FDA的欧洲同事过去在罕见疾病的治疗方面更加宽松，但arimoclomol可能不会向前推进，直到它产生一些令人信服的临床试验结果。</blockquote></p><p> Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p><p><blockquote>尽管缺乏明确的前进道路，这家总部位于丹麦的公司仍然拥有相当大的市值，按最近的价格计算，超过 5 亿美元。非理性的期望可能会使其保持较高水平，但对于任何临床阶段的生物技术公司 Orphazyme 的地位来说，这都太高了。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":2013,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166049168,"gmtCreate":1623986347054,"gmtModify":1634024593702,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575604969719218","authorIdStr":"3575604969719218"},"themes":[],"title":"","htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166049168","repostId":"2144713861","repostType":4,"isVote":1,"tweetType":1,"viewCount":3667,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166084840,"gmtCreate":1623985566380,"gmtModify":1634024623070,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575604969719218","authorIdStr":"3575604969719218"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166084840","repostId":"2144286417","repostType":4,"isVote":1,"tweetType":1,"viewCount":1821,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163258306,"gmtCreate":1623887070705,"gmtModify":1634026525929,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575604969719218","authorIdStr":"3575604969719218"},"themes":[],"title":"","htmlText":"Bad","listText":"Bad","text":"Bad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163258306","repostId":"1199737134","repostType":4,"repost":{"id":"1199737134","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623885157,"share":"https://www.laohunote.com/m/news/1199737134?lang=zh_CN&edition=full","pubTime":"2021-06-17 07:12","market":"us","language":"en","title":"Musk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>疫苗受挫后，马斯克吹捧的 CureVac 价值损失了 49%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199737134","media":"Tiger Newspress","summary":"Company plunges After Covid Shot Falls Short With 47% Efficacy\nEffectiveness is far below that seen ","content":"<p><ul> <li>Company plunges After Covid Shot Falls Short With 47% Efficacy</li> <li>Effectiveness is far below that seen with other mRNA vaccines</li> </ul> CureVac NV shares plunged after a preliminary analysis of a large study muddied by the spread of virus variants found its Covid-19 vaccine was 47% effective, well short of the high bar set by other messenger RNA shots.</p><p><blockquote><ul><li>新冠疫苗有效率低于 47%，公司股价暴跌</li><li>有效性远低于其他mRNA疫苗</li></ul>CureVac NV 股价暴跌，此前一项大型研究的初步分析发现，其 Covid-19 疫苗的有效率为 47%，远低于其他信使 RNA 疫苗设定的高标准。</blockquote></p><p> The interim analysis of data from about 40,000 volunteers included 134 Covid cases, the German company said in a statement. CureVac declined to say how many who got the shot got sick or how many received a placebo. But the results suggest the vaccine works less well for older people than in a younger population, Chief Technology Officer Mariola Fotin-Mleczek said in an interview Wednesday.</p><p><blockquote>这家德国公司在一份声明中表示，对约 40,000 名志愿者数据的中期分析包括 134 例 Covid 病例。CureVac 拒绝透露有多少注射者生病，或者有多少人接受了安慰剂。但首席技术官 Mariola Fotin-Mleczek 在周三接受采访时表示，结果表明，该疫苗对老年人的效果不如对年轻人好。</blockquote></p><p> Though preliminary, the results throw the future of the vaccine into question as wealthy nations around the world move swiftly to inoculate their populations with shots already available. Still, CureVac will finish its trial and plans to gain approval, Chief Executive Officer Franz-Werner Haas said.</p><p><blockquote>尽管是初步的，但随着世界各地的富裕国家迅速采取行动，用已经可用的疫苗为其人口接种疫苗，这些结果使疫苗的未来受到质疑。尽管如此，CureVac 首席执行官 Franz-Werner Haas 表示，CureVac 仍将完成试验并计划获得批准。</blockquote></p><p> “There is a huge need for vaccine, and I think we can still make a contribution,” Haas said.</p><p><blockquote>“哈斯说：”对疫苗的需求非常大，我认为我们仍然可以做出贡献。</blockquote></p><p> The company’s shares fell more than 49% in post-market trading after being up 17% this year through Wednesday’s close.</p><p><blockquote>截至周三收盘，该公司股价今年上涨了 17%，但在盘后交易中下跌了 49% 以上。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6ec3f2e05cfbc6c7d87c3fa174f459c\" tg-width=\"1302\" tg-height=\"663\"></p><p><blockquote></blockquote></p><p> In April, Elon Musk tweeted about CureVac, which Tesla Inc. has partnered with on a vaccine printer,saying it “sounds like they’re a few months away from regulatory approval.” He added that “a tidal wave of vaccine is coming this summer.” He later deleted the tweet.</p><p><blockquote>今年 4 月，埃隆-马斯克（Elon Musk）在推特上谈到了 CureVac，称 “听起来他们离监管部门的批准还有几个月的时间”。他补充说，“今年夏天将出现一波疫苗接种浪潮”。他后来删除了这条推文。</blockquote></p><p> The shot could be a boost in the developing world, since it doesn’t require the deep freezing needed for other Covid shots. Partly owned by the German government, CureVac has forged partnerships with Bayer AG,GlaxoSmithKline Plc and the U.K. government aimed at speeding production of its shot and future versions that will target mutated strains.</p><p><blockquote>这种注射可能会对发展中国家起到推动作用，因为它不需要其他 Covid 注射所需的深度冷冻。CureVac 部分归德国政府所有，已与拜耳公司、葛兰素史克公司和英国建立了合作伙伴关系。政府的目标是加快其疫苗的生产，以及针对突变菌株的未来版本。</blockquote></p><p> The data comes as the world is at something of a crossroads in the Covid fight, with global infections falling even as outbreaks in places with less access to vaccines serve as a reminder that the pandemic is far from over. The wealthiest countries have taken an outsize share of the more than 2.4 billion shots administered so far.</p><p><blockquote>这些数据发布之际，世界正处于抗击新冠疫情的十字路口，全球感染人数正在下降，尽管疫苗较少的地方爆发疫情提醒人们，疫情远未结束。迄今为止，最富裕的国家已经在超过24亿次注射中占据了很大一部分。</blockquote></p><p> The proliferation of variants in the CureVac trial is testimony to how the pandemic has changed since the first large vaccine clinical trials were run last year.</p><p><blockquote>CureVac试验中变异体的扩散证明了自去年进行第一次大型疫苗临床试验以来，疫情发生了怎样的变化。</blockquote></p><p> <b>Genetic Sequencing</b></p><p><blockquote><b>基因测序</b></blockquote></p><p> CureVac’s researchers genetically sequenced 124 of the 134 cases they included in their analysis. Just one of the sequenced cases was due to the original SARS-CoV-2 virus first identified in Wuhan, China. The rest came from a range of variants, including 21% of cases attributable to a new variant called lambda that was first identified in Peru.</p><p><blockquote>CureVac 的研究人员对他们分析中包含的 134 个病例中的 124 个进行了基因测序。只有一例测序病例是由中国武汉首次发现的原始新型冠状病毒病毒引起的。其余的来自一系列变种，包括21%的病例可归因于在秘鲁首次发现的一种名为lambda的新变种。</blockquote></p><p> TheWorld Health Organization added lambda to its watchlist as a variant of interest on Monday.</p><p><blockquote>世界卫生组织周一将 lambda 列入其观察名单，作为感兴趣的变体。</blockquote></p><p> Some 57% of the Covid cases in the study were due to so-called variants of concern, the four variants that the World Health Organization has deemed the most worrying. Most of these -- about 41% of all the cases -- were due to the alpha variant first observed in the U.K., CureVac said.</p><p><blockquote>研究中约57%的Covid病例是由所谓的令人担忧的变异引起的，这是世界卫生组织认为最令人担忧的四种变异。CureVac 表示，其中大部分（约占所有病例的 41%）是由英国首次观察到的 alpha 变种引起的。</blockquote></p><p> That variant is now the most common in the U.S., and other vaccines, including shots from Pfizer Inc. and BioNTech SE as well as Novavax Inc., have shown themselves effective against it. CureVac didn’t release detailed data about how its shot performed against each of the variants.</p><p><blockquote>这种变异现在在美国最常见，其他疫苗，包括辉瑞公司和BioNTech SE以及Novavax公司的疫苗，都已被证明对它有效。CureVac 没有公布其针对每种变种的注射效果的详细数据。</blockquote></p><p> <b>Final Readout</b></p><p><blockquote><b>最终读数</b></blockquote></p><p> More details will emerge in the final readout of the study, which will include more than 200 Covid cases and could come within two or three weeks, CureVac said.</p><p><blockquote>CureVac 表示，更多细节将出现在该研究的最终读数中，该研究将包括 200 多个 Covid 病例，可能会在两到三周内公布。</blockquote></p><p> Like the shots from Moderna Inc. and the Pfizer-BioNtech alliance, CureVac’s vaccine relies on mRNA, enlisting the body’s own cells as vaccine factories. Unproven until last year, the technology has now catapulted to the forefront of the global fight against Covid.</p><p><blockquote>与 Moderna Inc. 和辉瑞-BioNtech 联盟的疫苗一样，CureVac 的疫苗依赖于 mRNA，利用人体自身的细胞作为疫苗工厂。直到去年才得到证实，这项技术现在已经跃居全球抗击新冠疫情的前沿。</blockquote></p><p> CureVac’s shot, though, is subtly different than its competitors, because it uses an unmodified form of mRNA.</p><p><blockquote>不过，CureVac 的疫苗与其竞争对手略有不同，因为它使用的是未经修饰的 mRNA。</blockquote></p><p> CureVac has said it plans to supply 300 million vaccine doses this year, enough to immunize 150 million people. Together with partners, it has said it will supply more than 1 billion doses in 2022.</p><p><blockquote>CureVac表示，计划今年供应3亿剂疫苗，足以为1.5亿人接种疫苗。该公司表示，将与合作伙伴一起在 2022 年供应超过 10 亿剂疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Musk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>疫苗受挫后，马斯克吹捧的 CureVac 价值损失了 49%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMusk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>疫苗受挫后，马斯克吹捧的 CureVac 价值损失了 49%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-06-17 07:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><ul> <li>Company plunges After Covid Shot Falls Short With 47% Efficacy</li> <li>Effectiveness is far below that seen with other mRNA vaccines</li> </ul> CureVac NV shares plunged after a preliminary analysis of a large study muddied by the spread of virus variants found its Covid-19 vaccine was 47% effective, well short of the high bar set by other messenger RNA shots.</p><p><blockquote><ul><li>新冠疫苗有效率低于 47%，公司股价暴跌</li><li>有效性远低于其他mRNA疫苗</li></ul>CureVac NV 股价暴跌，此前一项大型研究的初步分析发现，其 Covid-19 疫苗的有效率为 47%，远低于其他信使 RNA 疫苗设定的高标准。</blockquote></p><p> The interim analysis of data from about 40,000 volunteers included 134 Covid cases, the German company said in a statement. CureVac declined to say how many who got the shot got sick or how many received a placebo. But the results suggest the vaccine works less well for older people than in a younger population, Chief Technology Officer Mariola Fotin-Mleczek said in an interview Wednesday.</p><p><blockquote>这家德国公司在一份声明中表示，对约 40,000 名志愿者数据的中期分析包括 134 例 Covid 病例。CureVac 拒绝透露有多少注射者生病，或者有多少人接受了安慰剂。但首席技术官 Mariola Fotin-Mleczek 在周三接受采访时表示，结果表明，该疫苗对老年人的效果不如对年轻人好。</blockquote></p><p> Though preliminary, the results throw the future of the vaccine into question as wealthy nations around the world move swiftly to inoculate their populations with shots already available. Still, CureVac will finish its trial and plans to gain approval, Chief Executive Officer Franz-Werner Haas said.</p><p><blockquote>尽管是初步的，但随着世界各地的富裕国家迅速采取行动，用已经可用的疫苗为其人口接种疫苗，这些结果使疫苗的未来受到质疑。尽管如此，CureVac 首席执行官 Franz-Werner Haas 表示，CureVac 仍将完成试验并计划获得批准。</blockquote></p><p> “There is a huge need for vaccine, and I think we can still make a contribution,” Haas said.</p><p><blockquote>“哈斯说：”对疫苗的需求非常大，我认为我们仍然可以做出贡献。</blockquote></p><p> The company’s shares fell more than 49% in post-market trading after being up 17% this year through Wednesday’s close.</p><p><blockquote>截至周三收盘，该公司股价今年上涨了 17%，但在盘后交易中下跌了 49% 以上。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6ec3f2e05cfbc6c7d87c3fa174f459c\" tg-width=\"1302\" tg-height=\"663\"></p><p><blockquote></blockquote></p><p> In April, Elon Musk tweeted about CureVac, which Tesla Inc. has partnered with on a vaccine printer,saying it “sounds like they’re a few months away from regulatory approval.” He added that “a tidal wave of vaccine is coming this summer.” He later deleted the tweet.</p><p><blockquote>今年 4 月，埃隆-马斯克（Elon Musk）在推特上谈到了 CureVac，称 “听起来他们离监管部门的批准还有几个月的时间”。他补充说，“今年夏天将出现一波疫苗接种浪潮”。他后来删除了这条推文。</blockquote></p><p> The shot could be a boost in the developing world, since it doesn’t require the deep freezing needed for other Covid shots. Partly owned by the German government, CureVac has forged partnerships with Bayer AG,GlaxoSmithKline Plc and the U.K. government aimed at speeding production of its shot and future versions that will target mutated strains.</p><p><blockquote>这种注射可能会对发展中国家起到推动作用，因为它不需要其他 Covid 注射所需的深度冷冻。CureVac 部分归德国政府所有，已与拜耳公司、葛兰素史克公司和英国建立了合作伙伴关系。政府的目标是加快其疫苗的生产，以及针对突变菌株的未来版本。</blockquote></p><p> The data comes as the world is at something of a crossroads in the Covid fight, with global infections falling even as outbreaks in places with less access to vaccines serve as a reminder that the pandemic is far from over. The wealthiest countries have taken an outsize share of the more than 2.4 billion shots administered so far.</p><p><blockquote>这些数据发布之际，世界正处于抗击新冠疫情的十字路口，全球感染人数正在下降，尽管疫苗较少的地方爆发疫情提醒人们，疫情远未结束。迄今为止，最富裕的国家已经在超过24亿次注射中占据了很大一部分。</blockquote></p><p> The proliferation of variants in the CureVac trial is testimony to how the pandemic has changed since the first large vaccine clinical trials were run last year.</p><p><blockquote>CureVac试验中变异体的扩散证明了自去年进行第一次大型疫苗临床试验以来，疫情发生了怎样的变化。</blockquote></p><p> <b>Genetic Sequencing</b></p><p><blockquote><b>基因测序</b></blockquote></p><p> CureVac’s researchers genetically sequenced 124 of the 134 cases they included in their analysis. Just one of the sequenced cases was due to the original SARS-CoV-2 virus first identified in Wuhan, China. The rest came from a range of variants, including 21% of cases attributable to a new variant called lambda that was first identified in Peru.</p><p><blockquote>CureVac 的研究人员对他们分析中包含的 134 个病例中的 124 个进行了基因测序。只有一例测序病例是由中国武汉首次发现的原始新型冠状病毒病毒引起的。其余的来自一系列变种，包括21%的病例可归因于在秘鲁首次发现的一种名为lambda的新变种。</blockquote></p><p> TheWorld Health Organization added lambda to its watchlist as a variant of interest on Monday.</p><p><blockquote>世界卫生组织周一将 lambda 列入其观察名单，作为感兴趣的变体。</blockquote></p><p> Some 57% of the Covid cases in the study were due to so-called variants of concern, the four variants that the World Health Organization has deemed the most worrying. Most of these -- about 41% of all the cases -- were due to the alpha variant first observed in the U.K., CureVac said.</p><p><blockquote>研究中约57%的Covid病例是由所谓的令人担忧的变异引起的，这是世界卫生组织认为最令人担忧的四种变异。CureVac 表示，其中大部分（约占所有病例的 41%）是由英国首次观察到的 alpha 变种引起的。</blockquote></p><p> That variant is now the most common in the U.S., and other vaccines, including shots from Pfizer Inc. and BioNTech SE as well as Novavax Inc., have shown themselves effective against it. CureVac didn’t release detailed data about how its shot performed against each of the variants.</p><p><blockquote>这种变异现在在美国最常见，其他疫苗，包括辉瑞公司和BioNTech SE以及Novavax公司的疫苗，都已被证明对它有效。CureVac 没有公布其针对每种变种的注射效果的详细数据。</blockquote></p><p> <b>Final Readout</b></p><p><blockquote><b>最终读数</b></blockquote></p><p> More details will emerge in the final readout of the study, which will include more than 200 Covid cases and could come within two or three weeks, CureVac said.</p><p><blockquote>CureVac 表示，更多细节将出现在该研究的最终读数中，该研究将包括 200 多个 Covid 病例，可能会在两到三周内公布。</blockquote></p><p> Like the shots from Moderna Inc. and the Pfizer-BioNtech alliance, CureVac’s vaccine relies on mRNA, enlisting the body’s own cells as vaccine factories. Unproven until last year, the technology has now catapulted to the forefront of the global fight against Covid.</p><p><blockquote>与 Moderna Inc. 和辉瑞-BioNtech 联盟的疫苗一样，CureVac 的疫苗依赖于 mRNA，利用人体自身的细胞作为疫苗工厂。直到去年才得到证实，这项技术现在已经跃居全球抗击新冠疫情的前沿。</blockquote></p><p> CureVac’s shot, though, is subtly different than its competitors, because it uses an unmodified form of mRNA.</p><p><blockquote>不过，CureVac 的疫苗与其竞争对手略有不同，因为它使用的是未经修饰的 mRNA。</blockquote></p><p> CureVac has said it plans to supply 300 million vaccine doses this year, enough to immunize 150 million people. Together with partners, it has said it will supply more than 1 billion doses in 2022.</p><p><blockquote>CureVac表示，计划今年供应3亿剂疫苗，足以为1.5亿人接种疫苗。该公司表示，将与合作伙伴一起在 2022 年供应超过 10 亿剂疫苗。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVAC":"CureVac B.V."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199737134","content_text":"Company plunges After Covid Shot Falls Short With 47% Efficacy\nEffectiveness is far below that seen with other mRNA vaccines\n\nCureVac NV shares plunged after a preliminary analysis of a large study muddied by the spread of virus variants found its Covid-19 vaccine was 47% effective, well short of the high bar set by other messenger RNA shots.\nThe interim analysis of data from about 40,000 volunteers included 134 Covid cases, the German company said in a statement. CureVac declined to say how many who got the shot got sick or how many received a placebo. But the results suggest the vaccine works less well for older people than in a younger population, Chief Technology Officer Mariola Fotin-Mleczek said in an interview Wednesday.\nThough preliminary, the results throw the future of the vaccine into question as wealthy nations around the world move swiftly to inoculate their populations with shots already available. Still, CureVac will finish its trial and plans to gain approval, Chief Executive Officer Franz-Werner Haas said.\n“There is a huge need for vaccine, and I think we can still make a contribution,” Haas said.\nThe company’s shares fell more than 49% in post-market trading after being up 17% this year through Wednesday’s close.\n\nIn April, Elon Musk tweeted about CureVac, which Tesla Inc. has partnered with on a vaccine printer,saying it “sounds like they’re a few months away from regulatory approval.” He added that “a tidal wave of vaccine is coming this summer.” He later deleted the tweet.\nThe shot could be a boost in the developing world, since it doesn’t require the deep freezing needed for other Covid shots. Partly owned by the German government, CureVac has forged partnerships with Bayer AG,GlaxoSmithKline Plc and the U.K. government aimed at speeding production of its shot and future versions that will target mutated strains.\nThe data comes as the world is at something of a crossroads in the Covid fight, with global infections falling even as outbreaks in places with less access to vaccines serve as a reminder that the pandemic is far from over. The wealthiest countries have taken an outsize share of the more than 2.4 billion shots administered so far.\nThe proliferation of variants in the CureVac trial is testimony to how the pandemic has changed since the first large vaccine clinical trials were run last year.\nGenetic Sequencing\nCureVac’s researchers genetically sequenced 124 of the 134 cases they included in their analysis. Just one of the sequenced cases was due to the original SARS-CoV-2 virus first identified in Wuhan, China. The rest came from a range of variants, including 21% of cases attributable to a new variant called lambda that was first identified in Peru.\nTheWorld Health Organization added lambda to its watchlist as a variant of interest on Monday.\nSome 57% of the Covid cases in the study were due to so-called variants of concern, the four variants that the World Health Organization has deemed the most worrying. Most of these -- about 41% of all the cases -- were due to the alpha variant first observed in the U.K., CureVac said.\nThat variant is now the most common in the U.S., and other vaccines, including shots from Pfizer Inc. and BioNTech SE as well as Novavax Inc., have shown themselves effective against it. CureVac didn’t release detailed data about how its shot performed against each of the variants.\nFinal Readout\nMore details will emerge in the final readout of the study, which will include more than 200 Covid cases and could come within two or three weeks, CureVac said.\nLike the shots from Moderna Inc. and the Pfizer-BioNtech alliance, CureVac’s vaccine relies on mRNA, enlisting the body’s own cells as vaccine factories. Unproven until last year, the technology has now catapulted to the forefront of the global fight against Covid.\nCureVac’s shot, though, is subtly different than its competitors, because it uses an unmodified form of mRNA.\nCureVac has said it plans to supply 300 million vaccine doses this year, enough to immunize 150 million people. Together with partners, it has said it will supply more than 1 billion doses in 2022.","news_type":1,"symbols_score_info":{"CVAC":0.9}},"isVote":1,"tweetType":1,"viewCount":2138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163039231,"gmtCreate":1623852908323,"gmtModify":1634027045880,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575604969719218","authorIdStr":"3575604969719218"},"themes":[],"title":"","htmlText":"Nice ","listText":"Nice ","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/163039231","repostId":"2143179480","repostType":4,"isVote":1,"tweetType":1,"viewCount":2129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187219093,"gmtCreate":1623755076912,"gmtModify":1634028973666,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575604969719218","authorIdStr":"3575604969719218"},"themes":[],"title":"","htmlText":"Hi everybody ","listText":"Hi everybody ","text":"Hi everybody","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187219093","isVote":1,"tweetType":1,"viewCount":1965,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187291162,"gmtCreate":1623754481656,"gmtModify":1634028988532,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575604969719218","authorIdStr":"3575604969719218"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187291162","repostId":"1122638224","repostType":4,"isVote":1,"tweetType":1,"viewCount":1402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}